

## Diabetes Update

Fall 2017  
Lyle Myers

### Section #1 OBJECTIVE

BE ABLE TO DIFFERENTIATE TYPE 1 FROM TYPE 2  
DIABETES

#### Clinical features:

- age at onset
- body weight/bmi
- family history
- treatment history
- hx of dka

#### Lab features to consider:

- Insulin level
- C-peptide level
- Islet antibodies
- GAD antibodies
- Anti- insulin antibodies

#### Typical features of Type 1 diabetes

- Age <4-
- Body weight at or near IBW at diagnosis
- Sparse family history of diabetes
- + serologies
- Low c-peptide/insulin levels

#### Typical features of type 2 diabetes

- Age >40
- Overweight
- Strongly positive family history
- Increased c-peptide/insulin level
- Negative serologies

### Typical Features of LADA

- Age +/- 40
- Weight- can be low, normal or high
- Family history: tends to be sparse
- C-peptide/insulin level may be normal
- Serologies are +
- Often will have been on OADs for a year or 2

### Case #1

- 52 yo wf
- Diagnosed type 2 age 48
- Treated with a variety of oral agents
- No family with diabetes
- Bmi 17
- A1c >11.
- Symptoms: wt loss and fatigue

### Case #1 (cont)

- Started her on basal insulin and stopped oad
- Ordered labs: gad, ica and c-peptide
- Gada +++, C-peptide 1.0, ICA negative
- What does she have?
- How would you treat her?

### Case #2

- 35 yo wm admitted to hospital with DKA and Sepsis due to a scrotal abscess
- treated in icu with iv insulin
- Sent home on basal/bolus insulin
- Bmi 42
- Father has type 2 diabetes.

### Case #2 (cont)

- 2 weeks later, seen in office.
- Smbg readings all normal on insulin.
- Labs showed: negative GADA and ICA
- C-peptide = 5.7
- What does he have ?

### Case #2 (continued)

Treatment- stayed on insulin for 2 months.  
Transitioned to oad's which he stayed on for 6 months  
Now, 5 years later, he is on no meds for diabetes  
And his a1c =4.8.

## Case #3

- 40 yo wm admitted in DKA
- No infection
- Bmi= 48
- No family history of diabetes
- Treated in icu with iv insulin
- Sent home on basal/ bolus insulin.
- What does he have?

## Case #3 (cont)

Labs: GADA +++, ICA +++, C-peptide = 1.7

Treatment: enrolled in research study for newly Diagnosed type 1 diabetics. Now on <10 units of Insulin /day with a1c <6.0

## Take home points:

- 1- not all newly diagnosed adults with diabetes are type 2
- 2- not all patients with DKA are type 1 diabetics
- 3- until you are sure what they have, it is safer to use insulin

## Section #2

Treating the blood sugar in type 2 diabetics

## Objectives:

- understand the biochemical defects
- Understand the mechanism of action for the
- Different classes of meds
- Identify goals and treatment strategies.

## BIOCHEMICAL DEFECTS

Insulin Resistance- liver, fat, muscle cells

Insulin deficiency- fasting  
- post prandial

Glucagon excess- post prandial

Appetite dysregulation

Excessive renal reabsorption of glucose

## Insulin resistance

liver- biguanide (metformin)  
Fat and Muscles- TZD's

### Insulin deficiency

- fasting- SU. Insulin. GLP1-RA
- post prandial- glinides, dpp4, glp1ra, insulin.

### Glucagon Excess

- Post prandial- DPP4/ GLP1ra

### Appetite Dysregulation

- GLP1RA

### Renal reabsorption of glucose

- SGLT 2 inhibitors.

### List of meds in each category

Biguanides: metformin

Tzds: pioglitazone

Sulfonylureas: glipizide, glyburide, glimepiride

Glinides: nateglinide

### List of meds (continued)

Insulins: long acting: levemir, lantus, toujeo  
basaglar, tresiba.  
Intermediate acting: NPH. U500 R  
Short acting : REGULAR  
Mixed: 70/30, 50/50, 75/25  
Fast acting : apidra, novolog, humalog

### List of meds:

DPP4 inhibitors: Januvia, onglyza, tradjenta,  
nesina

GLP1 RA: Byetta, Bydureon, Victoza, Trulicity Tanzeum

SGLT2 inhibitors: Jardiance, Farxiga and Invokana

## Side effects

- ▶ Biguanides: gastrointestinal
- ▶ TZDs: wt gain, edema, chf
- ▶ SFU/ Glinides: wt gain, hypos
- ▶ Insulin: wt gain, hypos
- ▶ Dpp4i: musculoskeletal pain, pancreatitis, Tschf
- ▶ GLP1: pancreatitis, MTC. GI side effects.
- ▶ SGLT2: UTI, GMI, volume depletion

## Beneficial effects

- ▶ Weight loss, no hypos. ? c/v benefit
- ▶ No hypos.
- ▶ Cheap
- ▶ Effectiveness
- ▶ No hypos. Weight neutral
- ▶ Wt loss, no hypos. C/V benefit\*
- ▶ C/V benefit\*, wt loss, no hypos

With all of the options, how do we choose which medications to use ?

We let the guidelines help us !

The AACE and ADA guidelines are slightly different.  
Pick one and try to be consistent

I keep a copy of the AACE guidelines on my desk.

### Case # 1.

45 yo wm comes to the doc for routine physical  
FBG = 176. A1c= 7.4, BMI 42. Strong family history of diabetes.

- Sent for dietary education
- Advised about exercise
- Started on metformin.
- 3 months later. Down 6 pounds and a1c =6.8

The story continues---

Patient returns 6 months later. A1c 7.2  
Was advised to be more attentive to diet and exercise  
Does not follow up for a year then and sees a different Provider. A1c 7.6. Blamed high blood sugar on stress.  
No med changes. Insurance changed and patient could Not follow up in that clinic. Returns 5 years later  
On no meds for diabetes and a1c >8.5. So a1c now >7  
For almost 7 years.

pt was put on metformin + GLP1.  
 3 months later a1c 7.2.. SGLT2 was added  
 3 months later a1c. 6.4..  
 1 year later.. Now a1c still 6.4

What does this case tell us?

#### Case #2

50 yo woman calls to come in because of wt loss  
 Polyuria, polydipsia and fatigue.  
 A1c 11. random bg 358.  
 BMI 42. + family hx. EGFR- 120.  
 How would you start her treatment?

I chose to put her on metformin + basal insulin  
 And referred for diabetes education.

1 month later, symptoms abated and fsbs were  
 In the 90-130 range fasting .  
 She had gained 11 pounds.

I switched insulin to a glp1. 3 months later  
 A1c is 6.7 and she is down 15 pounds.

Care is ongoing because diabetes is relentless.